Humana Inc. $HUM Stock Holdings Decreased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. lowered its position in shares of Humana Inc. (NYSE:HUM) by 4.1% during the first quarter, Holdings Channel reports. The fund owned 37,695 shares of the insurance provider’s stock after selling 1,603 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Humana were worth $6,483,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Humana by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after purchasing an additional 106,030 shares during the period. Capital International Investors grew its holdings in shares of Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after buying an additional 3,097,571 shares in the last quarter. Pzena Investment Management LLC raised its position in Humana by 34.3% during the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock valued at $948,614,000 after buying an additional 1,398,774 shares during the period. State Street Corp raised its position in Humana by 1.8% during the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock valued at $1,403,877,000 after buying an additional 97,211 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in Humana by 28.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock worth $1,151,759,000 after acquiring an additional 1,008,514 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 1.3%

NYSE HUM traded down $5.00 on Friday, reaching $392.76. The stock had a trading volume of 1,788,183 shares, compared to its average volume of 1,385,265. The business has a 50 day moving average price of $338.80 and a 200 day moving average price of $255.19. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $415.00. The company has a market capitalization of $47.16 billion, a price-to-earnings ratio of 42.01, a P/E/G ratio of 2.24 and a beta of 0.71.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same period in the prior year, the firm posted $11.58 EPS. The business’s revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. On average, analysts forecast that Humana Inc. will post 9.03 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a yield of 0.9%. Humana’s dividend payout ratio is currently 37.86%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Cantor Fitzgerald raised their price objective on Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 7th. Zacks Research raised shares of Humana from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 13th. Raymond James Financial set a $300.00 price target on shares of Humana in a report on Tuesday, July 7th. Guggenheim boosted their price objective on shares of Humana from $252.00 to $269.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Robert W. Baird dropped their price objective on shares of Humana from $264.00 to $205.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $303.74.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.